Внепечёночные причины заболеваемости и смертности реципиентов печени в отдалённом посттрансплантационном периоде

Внепечёночные причины заболеваемости и смертности реципиентов печени в отдалённом посттрансплантационном периоде

Автор: Восканян С.Э., Сюткин В.Е., Сушков А.И., Восканян Ю.В., Веселкова А.Ю., Лукьянчикова А.С., Кучеров А.А.

Журнал: Вестник медицинского института "РЕАВИЗ": реабилитация, врач и здоровье @vestnik-reaviz

Рубрика: Донорство и трансплантация органов и тканей

Статья в выпуске: 4 т.13, 2023 года.

Бесплатный доступ

В настоящее время годичная выживаемость пациентов, перенёсших трансплантацию печени, составляет 80-90 %. В отдалённые сроки после операции сохраняются повышенные, по сравнению с общей популяцией, риски летального исхода. При этом в структуре смертности реципиентов внепеченочные причины превалируют над патологией трансплантата. Злокачественные новообразования, сердечно-сосудистые заболевания, инфекции, метаболические нарушения и болезни почек - ключевые факторы, оказывающие негативное влияние на отдалённые результаты трансплантаций. В статье приводится обзор и обобщение актуальных сведений о распространённости, структуре и прогностическом значении различных вариантов внепечёночной патологии у реципиентов печени в отдалённом послеоперационном периоде.

Еще

Трансплантация печени, отдалённые результаты, злокачественные новообразования, сердечно-сосудистые заболевания, инфекция, метаболические нарушения, болезни почек

Короткий адрес: https://sciup.org/143180696

IDR: 143180696   |   DOI: 10.20340/vmi-rvz.2023.4.TX.1

Список литературы Внепечёночные причины заболеваемости и смертности реципиентов печени в отдалённом посттрансплантационном периоде

  • Adam R, Karam V, Cailliez V, О Grady JG, Mirza D, Cherqui D et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR) -50-year evolution of liver transplantation. Transpl Int. 2018;31(12):1293-1317. https://doi.org/10.1111/tri.13358 PMID: 30259574.
  • Gelson W, Hoare M, Dawwas MF, Vowler S, Gibbs P, Alexander G. The pattern of late mortality in liver transplant recipients in the United Kingdom. Transplantation. 2011 ;91 (11 ):1240-1244. https://d0i.0rg/l 0.1097/TP.0b013e31821841 ba PMID: 21516069.
  • Vionnet J., Abraldes, Juan G. , Miquel R., et al. Immunological risk stratification of stable long-term liver transplant recipients employing noninvasive tools. OS-213. Program and abstracts of the THE INTERNATIONAL LIVER CONGRESS. 2021. J Hepatology. 75(Suppl.2): s.235-236
  • Schoening WN, Buescher N, Rademacher S, Andreou A, Kuehn S, Neuhaus R et al. Twenty-year longitudinal follow-up after orthotopic liver transplantation: a single-center experience of 313 consecutive cases. Am J Transplant. 2013;13(9):2384-2394. https://doi.org/10.1111/ajt.12384 PMID: 23915357.
  • Agopian VG, Petrowsky H, Kaldas FM, Zarrinpar A, Farmer DG, Yersiz H et al. The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center. Ann Surg. 2013;258(3):409-421. https://doi.org/10.1097/SLA.0b013e3182a15db4 PMID: 24022434.
  • Young K, Liu B, Bhuket T, Wong RJ. Lower Likelihood of Post-transplant Graft Failure, Death, and Retransplantation in the Era of Direct-Acting Antivirals. J Clin Exp Hepatol. 2020;10(6):581-589. https://doi.Org/10.1016/j.jceh.2020.02.003 PMID: 33311895
  • Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert К et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg. 2000;232(4):490-500. https://doi.org/10.1097/00000658-200010000-00004 PMID: 10998647
  • Koshy AN, Gow PJ, Han HC, Teh AW, Jones R, Testro A et al. Cardiovascular mortality following liver transplantation: predictors and temporal trends over 30 years. Eur Heart J Qual Care Clin Outcomes. 2020;6(4):243-253. https://doi.org/10.1093/ehjqcco/qcaa009 PMID: 32011663
  • Jain A, Singhal A, Fontes P, Mazariegos G, DeVera ME, Cacciarelli T et al. One thousand consecutive primary liver transplants under tacrolimus immunosuppression: a 17- to 20-year longitudinal follow-up. Transplantation. 2011;91(9):1025-1030. https://d0i.0rg/l 0.1097ЯР.0Ь013е3182129215 PMID: 21378604
  • Aberg F, Gissler M, Karlsen TH, Ericzon BG, Foss A, Rasmussen A et al. Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study. Hepatology. 2015;61 (2):668-677. https://doi.org/10.1002/hep.27538
  • Barber K, Blackwell J, Collett D, Neuberger J; UK Transplant Liver Advisory Group. Life expectancy of adult liver allograft recipients in the UK. Gut. 2007;56(2):279-282. https://doi.org/10.1136/gut.2006.093195 PMID: 17008365
  • Rabkin JM, de La Melena V, Orloff SL, Corless CL, Rosen HR, Olyaei AJ. Late mortality after orthotopic liver transplantation. Am J Surg. 2001; 181 (5):475-479. https://d0i.0rg/l 0.1016/s0002-9610(01)00595-5 PMID: 11448447
  • Vogt DP, Henderson JM, Carey WD, Barnes D. The long-term survival and causes of death in patients who survive at least 1 year after liver transplantation. Surgery. 2002;132(4):775-780. https://doi.org/10.1067/msy.2002.128343 PMID: 12407365
  • Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant. 2010;10(6):1420-1427. https://d0i.0rg/l 0.1111/j.1600-6143.2010.03126.x PMID: 20486907
  • De Luca L, Kalafateli M, Bianchi S, Alasaker N, Buzzetti E, Rodriguez-Peralvarez M et al. Cardiovascular morbidity and mortality is increased post-liver transplantation even in recipients with no pre-existing risk factors. Liver Int. 2019;39(8):1557-1565. https://doi.Org/10.1111 /liv. 14185 PMID: 31233663
  • Egeli T, Unek T, Agalar C, Derici S, Ozbilgin M, Akarasu M et al. Analysis of Causes and Risk Factors for Late Mortality After Liver Transplant: How Can We Obtain Better Long-Term Survival? Exp Clin Transplant. 2020;18(2): 182-187. https://d0i.0rg/l 0.6002/ect.2017.0346 PMID: 29863452
  • Мальцева А.П., Сюткин B.E., Колышев И.Ю., Рудаков B.C., Светлакова Д.С., Садыхов З.А. и соавт. Трансплантация в онкологии -будущее мультидисциплинарного подхода. Трансплантология. 2019;11(3):218-233. https://d0i.0rg/l 0.23873/2074-0506-2019-11-3-218-233 [Maltseva A.P., Syutkin V.E., Kolyshev I.Yu., Rudakov V.S., Svetlakova D.S., Sadykhov Z.A. et al. Transplantation in oncology: the future of a multidisciplinary approach. Transplantologiya. The Russian Journal of Transplantation. 2019;11 (3): 218-233.
  • Grundy SM, Brewer HB Jr, Cleeman Jl, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433-438. https://doi.Org/10.1161/01 .CIR.0000111245.75752.C6 PMID: 14744958
  • Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469-480. https://doi.Org/10.1111/j. 1464-5491.2006.01858.x PMID: 16681555
  • Anastácio LR, Lima AS, Toulson Davisson Correia Ml. Metabolic syndrome and its components after liver transplantation: incidence, prevalence, risk factors, and implications. Clin Nutr. 2010;29(2):175-179. https://doi.Org/10.1016/j.clnu.2009.08.008 PMID: 19783330
  • García-Pajares F, Peñas-Herrero I, Sánchez-Ocaña R, Torrres-Yuste R, Cimavilla-Román M, Carbajo-López A et al. Metabolic Syndrome After Liver Transplantation: Five-Year Prevalence and Risk Factors. Transplant Proc. 2016;48(9):3010-3012. https://doi.Org/10.1016/j.transprc>-ceed.2016.07.038 PMID: 27932133
  • Laryea M, Watt KD, Molinari M, Walsh MJ, McAlisterVC, Marotta PJ et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl. 2007;13(8):1109-1114. https://doi.org/10.1002/lt.21126 PMID: 17663411
  • Gitto S, de Maria N, di Benedetto F, Tarantino G, Serra V, Maroni L et al. De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients. Eur J Gastroenterol Hepatol. 2018;30(7):766-773. https://doi.org/10.1097/MEG.0000000000001105 PMID: 29505475
  • Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl. 2008;14(11 ):1648-1654. https://doi.org/10.1002/lt.21588 PMID: 18975273
  • Rezende Anastácio L, Garcia Ferreira L, Costa Liboredo J, de Sena Ribeiro H, Soares Lima A, Garcia Vilela E et al. Overweight, obesity and weight gain up to three years after liver transplantation. NutrHosp. 2012;27(4):1351 -1356. https://doi.Org/10.3305/nh.2012.27.4.5768 PMID: 23165585
  • Leonard J, Heimbach JK, Malinchoc M, Watt K, Charlton M. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant. 2008;8(3):667-672. https://doi.Org/10.1111/j.1600-6143.2007.02100.x PMID: 18294163
  • Thoefner LB, Rostved AA, Pommergaard HC, Rasmussen A. Risk factors for metabolic syndrome after liver transplantation: A systematic review and meta-analysis. Transplant Rev (Orlando). 2018;32(1):69-77. https://doi.Org/10.1016/j.trre.2017.03.004 PMID: 28501338
  • Gitto S, Magistri P, Marzi L, Mannelli N, De Maria N, Mega A et al. Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: A long-term follow-up study. Ann Hepatol. 2022;27(3):100683. https://doi.Org/10.1016/j.aohep.2022.100683 PMID: 35151902
  • Van Son J, Stam SP, Gomes-Neto AW, Osté MCJ, Blokzijl H, van den Berg AP et al. Post-transplant obesity impacts long-term survival after liver transplantation. Metabolism. 2020;106:154204. https://doi.Org/10.1016/j.metabol.2020.154204 PMID: 32173406
  • Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19(1):3-26. https://doi.org/10.1002/lt.23566 PMID: 23281277
  • Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol. 2010;53(1):199-206. https://doi.Org/10.1016/j.jhep.2010.01.040 PMID: 20451282
  • Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl. 2011 ;17(1 ):15-22. https://doi.org/10.1002/lt.22198 PMID: 21254340
  • Hüsing A, Kabar I, Schmidt HH. Lipids in liver transplant recipients. World J Gastroenterol. 2016;22(12):3315-3324. https://doi.org/10.3748/wjg.v22.i12.3315 PMID: 27022213
  • Kockx M, Kritharides L. Hyperlipidaemia in immunosuppression. Curr Opin Lipidol. 2016;27(6):631-632. https://doi.org/10.1097/MOL.0000000000000363 PMID: 27805973
  • Deleuze S, Garrigue V, Delmas S, Chong G, Swarcz I, Cristol JP et al. New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine? Transplant Proc. 2006;38(7):2311-2313. https://doi.Org/10.1016/j.transproceed.2006.06.125 PMID: 16980075
  • Agarwal A, Prasad GV. Post-transplant dyslipidemia: Mechanisms, diagnosis and management. World J Transplant. 2016;6(1): 125-134. https://doi.org/10.5500/wjt.v6.i1.125 PMID: 27011910
  • Seymen P, Yildiz M, Türkmen MF, Titiz Ml, Seymen HO. Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters. Transplant Proc. 2009;41(10):4181-4183. https://d0i.0rg/l 0.1016/j.transproceed.2009.09.069 PMID: 20005364
  • Manzarbeitia C, Reich DJ, Rothstein KD, Braitman LE, Levin S, Muñoz SJ. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients. Liver Transpl. 2001 ;7(2):93-99. https://doi.org/10.1053/jlts.2001.21289 PMID: 11172391
  • Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002;43(8):1170-1180. PMID: 12177161
  • Harper SJ, Gelson W, Harper IG, Alexander GJ, Gibbs P. Switching to sirolimus-based immune suppression after liver transplantation is safe and effective: a single-center experience. Transplantation. 2011 ;91 (1):128-132. https://doi.org/10.1097/tp.0b013e3181fe131b PMID: 21452417
  • Nguyen LS, Vautier M, Allenbach Y, Zahr N, Benveniste O, Funck-Brentano C et al. Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation. DrugSaf. 2019;42(7):813-825. https://doi.org/10.1007/s40264-019-00810-9 PMID: 30868436
  • Chhatrala R, Siddiqui MB, Stravitz RT, Driscoll C, Sanyal A, Sargeant C et al. Evolution of serum atherogenic risk in liver transplant recipients: Role of lipoproteins and metabolic and inflammatory markers. Liver Transpl. 2015;21(5):623-630. https://doi.org/10.1002/lt.24100 PMID: 25762084
  • Heisel O, Heisel R, Baishaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004;4(4):583-595. https://doi.Org/10.1046/j.1600-6143.2003.00372.x PMID: 15023151
  • Kuo HT, Sampaio MS, Ye X, Reddy P, Martin P, Bunnapradist S. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation. 2010;89(9):1134-1140. https://doi.org/10.1097/TP.0b013e3181d2fec1 PMID: 20386364
  • Demirci MS, Toz H, Yilmaz F, Ertilav M, Asci G, Ozkahya M et al. Risk factors and consequences of post-transplant diabetes mellitus. Clin Transplant. 2010;24(5):E170-E177. https://doi.Org/10.1111/j.1399-0012.2010.01247.x PMID: 20384711
  • Gitto S, De Maria N, Marzi L, Magistri P, Falcini M, Vitale G et al. Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study. Eur J Intern Med. 2020;79:70-75. https://doi.Org/10.1016/j.ejim.2020.05.041 PMID: 32616342
  • Roccaro GA, Goldberg DS, Hwang WT, Judy R, Thomasson A, Kimmel SE et al. Sustained Posttransplantation Diabetes Is Associated With Long-Term Major Cardiovascular Events Following Liver Transplantation. Am J Transplant. 2018;18(1):207-215. https://doi.org/10.1111/ajt.14401 PMID: 28640504
  • Albeldawi M, Aggarwal A, Madhwal S, Cywinski J, Lopez R, Eghtesad В et al. Cumulative risk of cardiovascular events after orthotopic liver transplantation. Liver Transpl. 2012;18(3):370-375. https://doi.org/10.1002/lt.22468 PMID: 22140067
  • John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl. 2002;8(8):708-713. https://doi.org/10.1053/jlts.2002.34638 PMID: 12149764
  • Moon Jl, Barbeito R, Faradji RN, Gaynor JJ, Tzakis AG. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: Long-term follow up. Transplantation. 2006;82(12):1625-1628. https://doi.org/10.1097/01.tp.0000250361.60415.96 PMID: 17198248
  • Younossi ZM, Stepanova M, Saab S, Kalwaney S, Clement S, Henry L et al. The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US. Aliment Pharmacol Ther. 2014;40(6):686-694. https://doi.org/10.1111/apt.12881 PMID: 25040315
  • Lv C, Zhang Y, Chen X, Huang X, Xue M, Sun Q et al. New-onset diabetes after liver transplantation and its impact on complications and patient survival. J Diabetes. 2015;7(6):881-890. https://doi.Org/10.1111/1753-0407.12275 PMID: 25676209
  • Yasodhara A, Dong V, Azhie A, Goldenberg A, Bhat M. Identifying Modifiable Predictors of Long-Term Survival in Liver Transplant Recipients With Diabetes Mellitus Using Machine Learning. Liver Transpl. 2021 ;27(4):536-547. https://doi.org/10.1002/lt.25930 PMID: 33113221
  • Canzanello VJ, Textor SC, Taler SJ, Schwartz LL, Porayko MK, Wiesner RH et al. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). Liver Transpl Surg. 1998;4(4):328-334. https://doi.org/10.1002/lt.500040404 PMID: 9649648
  • Lim KB, SchianoTD. Long-term outcome after liver transplantation. Mt Sinai J Med. 2012;79(2):169-189. https://doi.org/10.1002/msj.21302 PMID: 22499489
  • Textor SC, Wiesner R, Wilson DJ, Porayko M, Romero JC, Burnett JC Jr et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation. 1993;55(6):1332-1339. https://doi.org/10.1097/00007890-199306000-00023 PMID: 7685934
  • Neal DA, Gimson AE, Gibbs P, Alexander GJ. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight. Liver Transpl. 2001 ;7(6):533-539. https://doi.org/10.1053/jlts.2001.24637 PMID: 11443583
  • Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-e292. https://doi.org/10.1161/01.cir.0000441139.02102.80 PMID: 24352519
  • Konerman MA, Fritze D, Weinberg RL, Sonnenday CJ, Sharma P. Incidence of and Risk Assessment for Adverse Cardiovascular Outcomes After Liver Transplantation: A Systematic Review. Transplantation. 2017;101 (7):1645-1657. https://d0i.0rg/l 0.1097ЯР.0000000000001710 PMID: 28296809
  • Nicolau-Raducu R, Gitman M, Ganier D, Loss GE, Cohen AJ, Patel H et al. Adverse cardiac events after orthotopic liver transplantation: a cross-sectional study in 389 consecutive patients. Liver Transpl. 2015;21 (1 ):13-21. https://doi.org/10.1002/lt.23997 PMID: 25213120
  • Borg MA, van der Wouden EJ, Sluiter WJ, Slooff MJ, Haagsma EB, van den Berg AP. Vascular events after liver transplantation: a long-term follow-up study. Transpl Int. 2008;21 (1):74-80. https://doi.Org/10.1111/j.1432-2277.2007.00557.x PMID: 17868273
  • Di Maira T, Rubin A, Puchades L, Aguilera V, Vinaixa C, Garcia M et al. Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients. Liver Transpl. 2015;21(6):812-822. https://doi.org/10.1002/lt.24128 PMID: 27396823
  • VanWagner LB, Montag S, Zhao L, Allen NB, Lloyd-Jones DM, Das Aet al. Cardiovascular Disease Outcomes Related to Early Stage Renal Impairment After Liver Transplantation. Transplantation. 2018;102(7):1096-1107. https://d0i.0rg/l 0.1097ЯР.0000000000002175 PMID: 29557907
  • Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349(10):931 -940. https://doi.org/10.1056/NEJMoa021744 PMID: 12954741
  • Lamattina JC, Foley DP, Mezrich JD, Fernandez LA, Vidyasagar V, DAIessandro AM et al. Chronic kidney disease stage progression in liver transplant recipients. Clin J Am Soc Nephrol. 2011 ;6(8):1851 -1857. https://d0i.0rg/l 0.2215/CJN.00650111 PMID: 21784823
  • Rasaei N, Malekmakan L, Mashayekh M, Gholamabbas G. Chronic Kidney Disease Following Liver Transplant: Associated Outcomes and Predictors. Exp Clin Transplant. 2022;21 (2):93-103. https://doi.org/10.6002/ect.2022.0288 PMID: 36656117
  • Сюткин В.E., Салиенко А.А., Олисов О.Д., Журавель C.B., Новрузбеков М.С. Влияние раннего назначения эверолимуса на фоне снижения дозирования ингибиторов кальциневрина на функцию почек у реципиентов трансплантата печени при длительном наблюдении. Трансплантология. 2021 ; 13(2): 121-129. https://doi.org/10.23873/2074-0506-2021-13-2-121-129 [Syutkin V.E., Salienko А.А., Oli-sov O.D., Zhuravel S.V., Novruzbekov M.S. The effect of early everolimus administration on the renal function while reducing the dosage of calcineurin inhibitors in liver transplant recipients in a long-term follow-up. Transplantologiya. The Russian Journal of Transplantation. 2021 ; 13(2): 121 -129. https://d0i.0rg/l 0.23873/2074-0506-2021 -13-2-121 -129 (In Russ)]
  • Сюткин В.E., Салиенко А.А., Журавель C.B., Новрузбеков М.С. Изменение скорости клубочковой фильтрации у реципиентов печени после снижения экспозиции ингибиторов кальциневрина с одновременным назначением эверолимуса на протяжении первого года после конверсии иммуносупрессии. Вестник трансплантологии и искусственных органов. 2021 ;23(4):32-41. https://doi.org/10.15825/25/1995-1191-2021-4-32-41 [Syutkin V.E., Salienko А.А., Zhuravel S.V., Novruzbekov M.S. Changes in glomerular filtration rate in liver recipients after reduced exposure to calcineurin inhibitors with concomitant everolimus administration within the first year after immunosuppression conversion. Russian Journal of Transplantology and Artificial Organs. 2021 ;23(4):32-41. https://doi.org/10.15825/25/1995-1191-2021-4-32-41 (In Russ)]
  • Gijsen VM, Madadi P, Dube MP, Hesselink DA, Koren G, de Wildt SN. Tacrolimus-induced nephrotoxicity and genetic variability: a review. Ann Transplant. 2012;17(2):111-121. https://doi.org/10.12659/aot.883229 PMID: 22743729
  • Ader JL, Rostaing L. Cyclosporin nephrotoxicity: pathophysiology and comparison with FK-506. CurrOpin NephrolHypertens. 1998;7(5):539-545. https://doi.org/10.1097/00041552-199809000-00009 PMID: 9818201
  • Bahirwani R, Forde KA, Mu Y, Lin F, Reese P, Goldberg D et al. End-stage renal disease after liver transplantation in patients with pre-transplant chronic kidney disease. Clin Transplant. 2014;28(2):205-210. https://doi.org/10.1111/ctr.12298 PMID: 24382253
  • Sanchez EQ, Melton LB, Chinnakotla S, Randall HB, McKennaGJ, Ruiz R et al. Predicting renal failure after liver transplantation from measured glomerular filtration rate: review of up to 15 years of follow-up. Transplantation. 2010;89(2):232-235. https://d0i.0rg/l 0.1097ЯР.0Ь013е3181 c42ff9 PMID: 20098288
  • Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl. 2003;9(7):741 -747. https://doi.org/10.1053/jlts.2003.50113 PMID: 12827563
  • Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349(10):931-940. https://doi.org/10.1056/NEJMoa021744 PMID: 12954741
  • Fujinaga K, Usui M, Yamamoto N, Ishikawa E, Nakatani A, Kishiwada M et al. Hypertension and hepatitis С virus infection are strong risk factors for developing late renal dysfunction after living donor liver transplantation: significance of renal biopsy. Transplant Proc. 2014;46(3):804-810. https://doi.Org/10.1016/j.transproceed.2013.11.103 PMID: 24767353
  • Jin H, Wei Y, Qian Y, Zhang J, Xu Y, Zhou H et al. Renal histopathological lesions after liver transplantation: What can we find besides calcineurin inhibitor-induced nephrotoxicity?. BMC Nephrol. 2022;23(1):324. Published 2022 Sep 30. https://doi.org/10.1186/s12882-022-02952-y PMID: 36180855
  • Pillebout E, Nochy D, Hill G, Conti F, Antoine С, Calmus Y et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 2005;5(5):1120-1129. https://doi.Org/10.1111/j.1600-6143.2005.00852.x PMID: 15816895
  • Chan GS, Lam MF, Kwan L, Fung SH, Chan SC, Chan KW. Clinicopathological study of renal biopsies after liver transplantation. Hong Kong Med J. 2013; 19(1 ):27-32. PMID: 23378351
  • Allen AM, Kim WR, Therneau TM, Larson JJ, Heimbach JK, Rule AD. Chronic kidney disease and associated mortality after liver transplanta-tion-a time-dependent analysis using measured glomerular filtration rate. J Hepatol. 2014;61 (2):286-292. https://doi.Org/10.1016/j.jhep.2014.03.034 PMID: 24713190
  • Ramachandran J, Juneja R, John L, Dutta AK, Chen JW, Woodman RJ et al. Chronic kidney disease following liver transplantation: a South Australian experience. Transplant Proc. 2010;42(9):3644-3646. https://doi.Org/10.1016/j.transproceed.2010.06.022 PMID: 21094832
  • AI Riyami D, Alam A, Badovinac K, Ivis F, Trpeski L, Cantarovich M. Decreased survival in liver transplant patients requiring chronic dialysis: a Canadian experience. Transplantation. 2008;85(9):1277-1280. https://d0i.0rg/l 0.1097ЯР.0Ь013е31816c4e6b PMID: 18475183
  • Zhou J, Hu Z, Zhang Q, Li Z, Xiang J, Yan S et al. Spectrum of De Novo Cancers and Predictors in Liver Transplantation: Analysis of the Scientific Registry of Transplant Recipients Database. PLoS One. 2016;11(5):e0155179. https://doi.org/10.1371/journal.pone.0155179 PMID: 27171501
  • Piselli P, Verdirosi D, Cimaglia C, Busnach G, Fratino L, Ettorre GM et al. Epidemiology of de novo malignancies after solid-organ transplantation: immunosuppression, infection and other risk factors. Best Pract Res Clin Obstet Gynaecol. 2014;28(8):1251-1265. https://doi.Org/10.1016/j.bpobgyn.2014.08.007 PMID: 25209964
  • Sherston SN, Carroll RP, Harden PN, Wood KJ. Predictors of cancer risk in the long-term solid-organ transplant recipient. Transplantation. 2014;97(6):605-611. https://doi.org/10.1097/01.TP.0000436907.56425.5c PMID: 24202142
  • Shalaby S, Burra P. De novo and recurrent malignancy. Best Pract Res Clin Gastroenterol. 2020;46-47:101680. https://doi.Org/10.1016/j.bpg.2020.101680 PMID: 33158464
  • Habib SL, Rojna M. Diabetes and risk of cancer. ISRN Oncol. 2013;2013:583786. https://doi.Org/10.1155/2013/583786 PMID: 23476808
  • Сюткин В.E., Городецкий В.Р., Салиенко A.A., Пробатова H.A., Купрышина H.A., Новрузбеков М.С. Полная регрессия генерализованной плазмоцитомы лимфатических узлов у реципиента трансплантата печени на фоне конверсии иммуносупрессивной терапии с такроли-муса на эверолимус. Трансплантология. 2021 ;13(3):272-279. https://doi.org/10.23873/2074-0506-2021-13-3-272-279 [Syutkin V.E., Go-rodetskiy V.R., Salienko A.A., Probatova N.A., Kupryshina N.A., Novruzbekov M.S. Complete regression of generalized plasmacytoma of lymph nodes in a liver transplant recipient during the conversion of immunosuppressive therapy from tacrolimus to everolimus. Transplantologiya. The Russian Journal of Transplantation. 2021 ;13(3):272-279. https://doi.org/10.23873/2074-0506-2021-13-3-272-279 (In Russ)]
  • Саркома Капоши после трансплантации печени. Трансплантология. 2018;10(2): 126-141. https://doi.org/10.23873/2074-0506-2018-10-2-126-141 [Voskanyan S.E., Syutkin V.E., Mal'tseva А.Р., RudakovV.S., Svetlakova D.S., Davtyan A.A. et al. Hemophagocytic syndrome and Kaposi sarcoma after liver transplantation. Transplantologiya. The Russian Journal of Transplantation. 2018;10(2):126-141.
  • Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology. 2009;137(6):2010-2017. https://doi.Org/10.1053/j.gastro.2009.08.070 PMID: 19766646
  • European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016;64(2):433-485. https://doi.Org/10.1016/j.jhep.2015.10.006 PMID: 26597456
  • Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59(3):1144-1165. https://doi.org/10.1002/hep.26972 PMID: 24716201
Еще
Статья обзорная
SciUp 2024 © 2024 ©